Merck (MRK) Tops Q3 EPS by 8c, Lifts FY EPS Gudiance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
October 30, 2017 10:45 AM EDTUBS lowered its price target on Merck (NYSE: MRK) to $67.00 (from $72.00) while maintaining a Buy rating, following the announcement that management would push out results into early 2019 for Keynote-189 in lung cancer.
Analyst Marc Goodman notes a cautious outlook on the shares as... More
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM EDTLeerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results
Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.
... MoreMorgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM EDTMorgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $58.24 Friday.
... MoreBarclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM EDTBarclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).
Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More
